ClinicalTrials.gg
Not yet recruitingNCT07218653Updated Nov 20, 2026

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

An Early Phase 1 interventional study of Indomethacin and Placebo in Metabolic Syndrome, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Wisconsin, Madison · Early Phase 1, Interventional, and Basic science

How we know

Updated Nov 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Planned enrollment
173rd of 490
72 · median 48
Started
2026
with 16 others
Phase 1
23 of 578
5 open now
Primary completion
2031-07
later than 75 of 82 live
Registered
560th of 578
by date

Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 173rd largest by planned enrollment of the 490 interventional ones that give a count, is one of 17 that started in 2026, is one of 23 in phase 1, reaches primary completion later than 75 of the 82 other live ones, and was the 560th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 578 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.

Read the detailed description

The central hypothesis is that MetSyn decreases CBF more in females than males due in part to the sex-specific loss of COX vasodilation. This hypothesis is based on extensive preliminary data demonstrating MetSyn induces: 1) 3-fold larger reductions in CBF in females that abolish sex differences, 2) region-specific CBF reduction patterns, and 3) a greater loss of COX-mediated vasodilation in females.

This hypothesis is tested via three Specific Aims:

  • Aim 1: Determine the extent of sex differences in MetSyn-driven CBF reductions. The investigators hypothesize females with MetSyn will demonstrate larger decrements in global, grey matter and white matter CBF versus males.
  • Aim 2: Determine the sex-by-region interactions of MetSyn reductions in CBF. The investigators hypothesize females will demonstrate larger regional CBF declines-particularly in regions known to be impacted very early in brain pathologies and/or specifically impaired by insulin resistance.
  • Aim 3: Determine the role of COX signaling in mediating CBF changes in MetSyn. The investigators hypothesize COX vasodilation is reduced more in females than males with MetSyn.

All consented participants will conduct a screening visit with a blood panel to identify control vs MetSyn eligibility.

Once eligible, participants complete three laboratory visits (each lasting about 2 hours):

  1. Exercise Visit: VO2 Max, DEXA for adiposity quantification, NIH Toolbox to assess neurocognitive function
  2. MRI Visit 1: blinded to either Placebo or Indomethacin
  3. MRI Visit 2: blinded to either Placebo or Indomethacin
03

Conditions studied

  • Metabolic Syndrome

Browse trials for

Keywords

  • Cerebral Blood Flow
  • CBF
  • COX
  • Metabolic Syndrome
  • MetSyn
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Healthy Controls):

  • 18-45 years old
  • Normal fasting values for blood glucose (less than 100 g/dl)
  • Normal values for lipids (LDL cholesterol less than 130 mg/dl, triglycerides less than 150 mg/dl) and HDL (men greater than 40, women greater than 50 mg/dl)
  • Women must have a predictable menstrual cycle. Females will be studied on cycle days 1-7 to minimize sex hormone differences and their potential confounding effects on vascular outcomes. Oral are allowed, and women will be studied during their placebo phase.

Inclusion Criteria (Participants with Metabolic Syndrome):

  • 18-45 years old
  • Meet at least 3 of the 5 ATP MetSyn criteria. These are:

    1. Waist circumference greater than 102 cm (males) or 82 cm (females)
    2. Triglycerides greater than 150 mg/dL
    3. HDL cholesterol less than 40 mg/dL (males) or 50 mg/dL (females)
    4. Blood pressure greater than or equal to 130/85 mmHg
    5. Fasting plasma glucose greater than 110 mg/dL

Exclusion Criteria (Healthy Controls):

  • (BMI) greater than or equal to 25 kg/m2
  • Blood pressure over 130/80 mmHg
  • Meeting any of the 5 MetSyn criteria listed above.

Exclusion Criteria (all participants):

  • Current smoker, defined as more than 5 cigarettes over past 30 days
  • Current diagnosis or history of:

    • peripheral vascular disease
    • hepatic disease
    • renal disease
    • lung disease
    • gastrointestinal disorders/bleeding
    • hematologic disease
    • stroke
    • myocardial infarction
    • coronary heart disease
    • congestive heart failure
    • heart surgery
    • sleep apnea
    • diseases
    • traumatic brain injury, concussion, stroke, or seizures
    • Asthma
    • Polycystic ovarian syndrome
    • Type II diabetes
    • Currently pregnant or breastfeeding
    • Current musculoskeletal injury
    • Medication use known to influence cardiovascular function, other than contraceptive hormones. Broadly, the classes of drugs relate to treating blood pressure, diabetes, cholesterol.
    • Claustrophobia
  • Lactose intolerance
  • Magnesium-restricted diet
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Healthy controls

    Male and female participants 18-45 without Metabolic Syndrome. On study for 3 visits (up to 6 months). Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.

    Drug: Indomethacin · Drug: Placebo · Diagnostic Test: MRI

  • Experimental
    Metabolic Syndrome

    Male and female participants, age-matched with Healthy Controls, who have at least 3 defining symptoms of Metabolic Syndrome. Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.

    Drug: Indomethacin · Drug: Placebo · Diagnostic Test: MRI

Interventions

  • Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin (1.5 mg/kg) will be taken orally prior to one MRI study visit.

    Also known as: Indo

  • DrugPlacebo

    Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit.

    Also known as: Lactose

  • Diagnostic testMRI

    CBF testing will be performed on 3T MRI scanners (GE Healthcare)

    Also known as: Magnetic Resonance Imaging

06

What researchers measure

Primary outcomes

  1. Cerebral Blood Flow

    Data collected via MRI under one of 2 conditions: placebo or indomethacin.

    Time frame: data collected over 2 study visits that must be completed within 6 months

Secondary outcomes

  1. Cardiorespiratory Fitness: VO2 max

    Graded exercise test to assess maximal aerobic capacity, reported as VO2 max (milliliters of oxygen consumed per kilogram of body weight per minute)

    Time frame: data collected at one study visit (must be completed within 6 months)

  2. Body Fat Mass

    Dual-energy x-ray absorptiometry (DEXA) to measure fat mass.

    Time frame: data collected at one study visit (must be completed within 6 months)

  3. Cognitive Testing: Flanker Inhibitory Control and Attention

    NIH Toolbox to assess neurocognitive function. The Flanker test is a measure of executive function and is scored using a T-score where 100 is the average, higher scores indicate better performance.

    Time frame: data collected at one study visit (must be completed within 6 months)

  4. Cognitive Testing: Pattern Comparison Processing Speed Test

    NIH Toolbox to assess neurocognitive function. The Pattern Comparison Processing Speed Test measures how many correct responses the participant has within 90 seconds. There is a maximum of 130 items.

    Time frame: data collected at one study visit (must be completed within 6 months)

  5. Cognitive Testing: List Sorting Working Memory Test

    NIH Toolbox to assess neurocognitive function. The List Sorting Working Memory Test is a measure of recall and sorting. Participants scores reflect the number of items recalled and appropriately sorted up to 28 items maximum.

    Time frame: data collected at one study visit (must be completed within 6 months)

  6. Cognitive Testing: Dimensional Change Card Sort Test

    NIH Toolbox to assess neurocognitive function. The Dimensional Change Card Sort Test measures accuracy: the number of accurate responses, up to a maximum of 40.

    Time frame: data collected at one study visit (must be completed within 6 months)

  7. Cognitive Testing: Picture Vocabulary Test

    NIH Toolbox to assess neurocognitive function. The Picture Vocabulary Test has the participant hear a word and then pick from one of four pictures that best represents the word. It is scored using a T-score where 100 is the average, higher scores indicate better performance.

    Time frame: data collected at one study visit (must be completed within 6 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.

Of 17 phase 1 interventional studies under Metabolic Syndrome, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 56 months is above that.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Nov 2026
moved 2 times, Sep 29, 2026 – Nov 2, 2026
Show all 3 updates
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date
  2. Nov 2, 2026
    Start date Oct 2026→Nov 2026
    + 1 other change: verification date
  3. Sep 29, 2026
    Start date Sep 2026→Oct 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07218653
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Nov 2026 (estimated)
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Shawn Bolin, MS
Contact
sbolin@wisc.edu
608-263-6308
William Schrage, PhD
principal investigator · UW Madison

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indomethacin

Start the discussion